Please login to the form below

Not currently logged in
Email:
Password:

Keytruda

This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.

Merck’s Keytruda meets survival challenge in NSCLC

Merck’s Keytruda meets survival challenge in NSCLC

Merck’ s Keytruda meets survival challenge in NSCLC. Data showed that almost 70% of patients on the combo were still alive after 12 months. ... advanced, non-squamous NSCLC was significantly improved with Keytruda (pembrolizumab) plus chemo, with the

Latest news

  • BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

    on Keytruda (pembrolizumab) plus chemotherapy in this setting. ... Meanwhile, Keytruda is not yet approved to treat RCC but has several trials ongoing in this indication, including a phase III evaluation as a neoadjuvant therapy alongside surgery.

  • Merck’s Keytruda scores in frontline lung cancer yet again Merck’s Keytruda scores in frontline lung cancer yet again

    Merck’ s Keytruda scores in frontline lung cancer yet again. Drug improved overall survival as a monotherapy, which rival BMS’Opdivo was unable to show. ... In the KEYNOTE-042 trial, PD-1 inhibitor Keytruda (pembrolizumab) improved overall survival

  • Incyte/Merck trial failure bodes ill for IDO class Incyte/Merck trial failure bodes ill for IDO class

    Incyte/Merck trial failure bodes ill for IDO class. The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone. ... a form of skin cancer, but was unable to show any improvement over Keytruda alone on progression-free

  • Segmentation, evolved Segmentation, evolved

    In my work, I’m seeing numerous examples of similar contextual segmentation, with Merck’s Keytruda being perhaps the most salient.

  • Another Tecentriq win for Roche as Avastin combo boosts survival Another Tecentriq win for Roche as Avastin combo boosts survival

    Roche is hoping to replace Merck &Co/MSD’s Keytruda (pembrolizumab) with Tecentriq as the cornerstone of first-line NSCLC immunotherapy, unlocking one of the largest markets for cancer drugs, and

More from news
Approximately 97 fully matching, plus 127 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Merck’s success in oncology will likely continue, driven by Keytruda’s lead in the frontline non-small cell lung cancer setting, ”says Cai Xuan, senior analyst, oncology and haematology, GlobalData. ... Though its main competitor, BMS’Opdivo, was

  • Accelerating innovation Accelerating innovation

    That would be an ideal scenario, ”he said, but as to whether Ipsen has been talking to Merck &Co about its blockbuster immuno-oncology treatment Keytruda (pembrolizumab), he declined to comment.

  • Deal Watch January 2017 Deal Watch January 2017

    patent dispute over Keytruda (pembrolizumab) therefore avoiding a court appearance scheduled for later in the year. ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).

  • Deal Watch June 2016 Deal Watch June 2016

    The mRNA vaccines will also be assessed in combination with Keytruda on an exclusive basis. ... licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics